TauC3 Biologics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- (Upcoming)
- Latest Deal Amount
-
$25M
- Investors
-
9
TauC3 Biologics General Information
Description
Operator of a biopharmaceutical company intended to develop precision immunotherapies for the treatment of a subset of neurodegenerative diseases known as tauopathies. The company's technology is a humanized monoclonal antibody, uniquely targeting an especially noxious protein metabolite in the brain of patients with tau-related frontotemporal dementia and progressive supranuclear palsy, with the aim of halting or preventing the onset of disease, enabling patients to get a sustainable, healthy life with the treatment for their fatal disease.
Contact Information
Website
www.tauc3bio.comCorporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road
- Stevenage SG1 2FX
- England, United Kingdom
Corporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road
- Stevenage SG1 2FX
- England, United Kingdom
TauC3 Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | $25M | Upcoming | Pre-Clinical Trials | |||
| 6. Later Stage VC | Completed | Pre-Clinical Trials | ||||
| 5. Seed Round | Completed | Pre-Clinical Trials | ||||
| 4. Seed Round | 31-Mar-2022 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 28-Dec-2020 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 02-Nov-2020 | $148K | $148K | Completed | Pre-Clinical Trials | |
| 1. Spin-Off | 19-Jul-2019 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TauC3 Biologics Patents
TauC3 Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3135170-A1 | Anti-tauc3 antibodies and uses thereof | Pending | 05-Apr-2019 | ||
| EP-3946605-A1 | Anti-tauc3 antibodies and uses thereof | Pending | 05-Apr-2019 | ||
| US-11155609-B2 | Anti-tauc3 antibodies and uses thereof | Active | 05-Apr-2019 | ||
| US-12162930-B2 | Anti-tauc3 antibodies and uses thereof | Active | 05-Apr-2019 | ||
| US-20200407431-A1 | Anti-tauc3 antibodies and uses thereof | Active | 05-Apr-2019 | C07K16/18 |
TauC3 Biologics Signals
TauC3 Biologics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Joseph Ventures | Family Office | Minority | ||
| Northlea Partners | Venture Capital | Minority | ||
| Angel (individual) | Minority |
TauC3 Biologics FAQs
-
When was TauC3 Biologics founded?
TauC3 Biologics was founded in 2019.
-
Where is TauC3 Biologics headquartered?
TauC3 Biologics is headquartered in Stevenage, United Kingdom.
-
What is the size of TauC3 Biologics?
TauC3 Biologics has 6 total employees.
-
What industry is TauC3 Biologics in?
TauC3 Biologics’s primary industry is Drug Discovery.
-
Is TauC3 Biologics a private or public company?
TauC3 Biologics is a Private company.
-
What is TauC3 Biologics’s current revenue?
The current revenue for TauC3 Biologics is .
-
How much funding has TauC3 Biologics raised over time?
TauC3 Biologics has raised $6.56M.
-
Who are TauC3 Biologics’s investors?
, , Joseph Ventures, Northlea Partners, and are 5 of 9 investors who have invested in TauC3 Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process